Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Hepatol. 2014 Jan;60(1):127-34. doi: 10.1016/j.jhep.2013.08.024. Epub 2013 Sep 6.

The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.

Author information

  • 1Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • 2Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; Department of General Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan. Electronic address: taroy@m-kanazawa.jp.
  • 3Department of Pathology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.

Abstract

BACKGROUND & AIMS:

Recent evidence suggests that hepatocellular carcinoma can be classified into certain molecular subtypes with distinct prognoses based on the stem/maturational status of the tumor. We investigated the transcription program deregulated in hepatocellular carcinomas with stem cell features.

METHODS:

Gene and protein expression profiles were obtained from 238 (analyzed by microarray), 144 (analyzed by immunohistochemistry), and 61 (analyzed by qRT-PCR) hepatocellular carcinoma cases. Activation/suppression of an identified transcription factor was used to evaluate its role in cell lines. The relationship of the transcription factor and prognosis was statistically examined.

RESULTS:

The transcription factor SALL4, known to regulate stemness in embryonic and hematopoietic stem cells, was found to be activated in a hepatocellular carcinoma subtype with stem cell features. SALL4-positive hepatocellular carcinoma patients were associated with high values of serum alpha fetoprotein, high frequency of hepatitis B virus infection, and poor prognosis after surgery compared with SALL4-negative patients. Activation of SALL4 enhanced spheroid formation and invasion capacities, key characteristics of cancer stem cells, and up-regulated the hepatic stem cell markers KRT19, EPCAM, and CD44 in cell lines. Knockdown of SALL4 resulted in the down-regulation of these stem cell markers, together with attenuation of the invasion capacity. The SALL4 expression status was associated with histone deacetylase activity in cell lines, and the histone deacetylase inhibitor successfully suppressed proliferation of SALL4-positive hepatocellular carcinoma cells.

CONCLUSIONS:

SALL4 is a valuable biomarker and therapeutic target for the diagnosis and treatment of hepatocellular carcinoma with stem cell features.

Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

KEYWORDS:

AFP; CSC; Cancer stem cell; Chemosensitivity; EpCAM; Gene expression profile; HCC; HDAC; Hepatocellular carcinoma; HpSC-HCC; MH-HCC; NuRD; SAHA; SALL4; SBHA; Sal-like 4 (Drosophila); alpha fetoprotein; cancer stem cell; epithelial cell adhesion molecule; hepatic stem cell-like HCC; hepatocellular carcinoma; histone deacetylase; mature hepatocyte-like HCC; nucleosome remodeling and deacetylase; qRT-PCR; quantitative reverse transcription-polymerase chain reaction; suberic bis-hydroxamic acid; suberoylanilide hydroxamic acid

PMID:
24012616
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk